Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. Its focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.

Type
Public
HQ
Los Angeles, US
Founded
2010
Size (employees)
160 (est)
Puma Biotechnology was founded in 2010 and is headquartered in Los Angeles, US
Report incorrect company information

Key People/Management at Puma Biotechnology

Alan H. Auerbach

Alan H. Auerbach

Chief Executive Officer, President and Chairman of the Board
MBChB Richard Bryce MRCGP, MFPM

MBChB Richard Bryce MRCGP, MFPM

Chief Medical and Scientific Officer
Charles R. Eyler

Charles R. Eyler

Senior Vice President, Finance and Administration and Treasurer
B.Sc Hons Douglas Hunt

B.Sc Hons Douglas Hunt

Senior Vice President, Regulatory Affairs, Medical Writing and Project Management
Steven Lo

Steven Lo

Chief Commercial Officer

Puma Biotechnology Office Locations

Puma Biotechnology has offices in San Francisco and Los Angeles
Los Angeles, US (HQ)
10880 Wilshire Blvd
Show all (2)
Report incorrect company information

Puma Biotechnology Financials and Metrics

Puma Biotechnology Financials

Puma Biotechnology's revenue was reported to be $27.69 m in FY, 2017
USD

Revenue (Q1, 2018)

66.5 m

Gross profit (Q1, 2018)

60.1 m

Gross profit margin (Q1, 2018), %

90.4%

Net income (Q1, 2018)

(24.3 m)

EBIT (Q1, 2018)

(23.4 m)

Market capitalization (21-May-2018)

2 b

Closing share price (21-May-2018)

52.3

Cash (31-Mar-2018)

78.6 m

EV

1.9 b
Puma Biotechnology's current market capitalization is $2 b.
Annual
USDFY, 2013FY, 2016FY, 2017

Revenue

27.7 m

Cost of goods sold

5.6 m

Gross profit

22.1 m

Gross profit Margin, %

80%
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

66.5 m

Cost of goods sold

6.4 m

Gross profit

60.1 m

Gross profit Margin, %

90%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

43 m38.5 m31.6 m194.5 m81.7 m

Accounts Receivable

9.7 m

Inventories

2 m

Current Assets

96.4 m149.4 m223.5 m236.5 m106.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

51.3 m163.4 m55.4 m28.3 m155.5 m59.8 m23.6 m78.2 m57.8 m52.5 m105.1 m80.8 m78.6 m

Accounts Receivable

16.3 m

Inventories

2.7 m

Current Assets

110.6 m211.7 m183.6 m160.1 m316.7 m287.8 m254.7 m189.4 m153.7 m117.4 m204.6 m160.8 m111.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(54.7 m)(142 m)(239.3 m)(276 m)(292 m)

Depreciation and Amortization

423 k627 k776 k1.1 m2.8 m

Inventories

(2 m)

Accounts Payable

10.2 m4.3 m2.8 m2.2 m7.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(14.3 m)(19.8 m)(38.8 m)(35.8 m)(52.5 m)(64.7 m)(60.4 m)(71 m)(137.6 m)(203.4 m)(72.9 m)(150.7 m)(24.3 m)

Depreciation and Amortization

208 k455 k565 k277 k551 k1.3 m

Inventories

(713 k)

Accounts Payable

18.8 m18.4 m12.6 m10.4 m9.8 m7 m6.8 m3.1 m3.9 m4.5 m(4.2 m)
USDY, 2018

EV/EBIT

-83.3 x

EV/CFO

-311.5 x

Financial Leverage

3 x
Show all financial metrics
Report incorrect company information

Puma Biotechnology News and Updates

Report incorrect company information